Stockreport

Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares  (KNSA) 
Last kiniksa pharmaceuticals international, plc - class a ordinary shares earnings: 8/12 04:02 pm Check Earnings Report
PDF - Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 -- Statistically significant seco [Read more]